Compass Therapeutics shares are trading higher after Piper Sandler raised its price target on the stock from $4 to $6.benzinga_article·Aug 7 at 06:28 PMCMPX+0.42%
Compass Therapeutics Q2 2026 net loss widens 26.63% to $25.2 million; R&D expenses rise 19% to $19.6 millionPUBT·Aug 6 at 11:31 AMCMPX+0.42%
Diverging Micro-Data: What Cross-Sector Q2 Updates Signal for the Broader EconomyGlobal Report·Jul 21 at 09:13 AMAZO+0.51%CROX+1.31%
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 | CMPX Stock NewsStockTitan·Jul 17 at 06:42 AMCMPX+0.42%
Compass Showcases Promising Tovecimig Data, Eyes CommercializationTip Ranks·Jul 1 at 09:30 PMCMPX+0.42%
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagementTradingView·Jul 1 at 09:03 PMCMPX+0.42%
Compass Therapeutics sets Delaware, Massachusetts federal courts as exclusive venue for Securities Act claimsPUBT·Jun 23 at 10:01 AMCMPX+0.42%
Compass Therapeutics To Present Phase 1 Data Results Of CTX-8371 At ASCO 2026nasdaq·May 26 at 08:00 AMCMPX+0.42%
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target MaintainedTip Ranks·May 5 at 07:55 PMCMPX+0.42%
